Fertility-sparing treatment feasible in early endometrial cancer

This article originally appeared here.
Fertility-Sparing Tx Feasible in Early Endometrial Cancer
Fertility-Sparing Tx Feasible in Early Endometrial Cancer

(HealthDay News) -- For women with early-stage endometrial cancer (EC) and atypical complex hyperplasia (ACH), fertility-sparing treatment seems feasible, according to research published in the October issue of the American Journal of Obstetrics & Gynecology.

Ioannis D. Gallos, M.D., from the Birmingham Women's Hospital in the United Kingdom, and colleagues conducted a systematic review and meta-analysis to examine the regression, relapse, and live birth rates for women with EC and ACH who underwent fertility-sparing treatment. A total of 34 observational studies, involving 408 women with EC and 151 women with ACH were included.

The researchers found that, for EC, fertility-sparing treatment achieved a pooled regression rate of 76.2 percent, a relapse rate of 40.6 percent, and a live birth rate of 28 percent. The corresponding figures for ACH were 85.6, 26, and 26.3 percent. During follow-up, 3.6 percent of women were diagnosed with ovarian cancer (concurrent or metastatic), 1.9 percent of women (10 women) progressed to disease higher than stage I EC, and two of these 10 women died.

"In conclusion, this review of observational studies found a high chance of disease regression and encouraging live birth rates of early-stage EC and ACH with fertility-sparing treatment followed by assisted reproduction," the authors write. "Our systematic examination of the published literature confirms that there is only moderate-quality observational evidence to inform clinical practice, and results should be interpreted with caution."

Abstract
Full Text (subscription or payment may be required)

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs